Author:
Arora Sankalp,Zainaldin Carl,Bathini Srilakshmi,Gupta Udita,Worth Sarah,Bachiashvili Kimo,Bhatia Ravi,Godby Kelly,Jamy Omer,Rangaraju Sravanti,Diamond Barry,Oliver Josh D.,Salzman Donna,Di Stasi Antonio,Vachhani Pankit
Subject
Cancer Research,Oncology,Hematology
Reference20 articles.
1. Hypomethylating agents in combination with venetoclax for acute myeloid leukemia: update on clinical trial data and practical considerations for use;Mei;Am. J. Hematol.,2019
2. U.S. Food & Drug Administration, 2019. FDA approves venetoclax in combination for AML in adults. December 17, 2018. 2019.
3. The efficacy and adverse events of venetoclax in combination with hypomethylating agents treatment for patients with acute myeloid leukemia and myelodysplastic syndrome: a systematic review and meta-analysis;Guo;Hematology,2020
4. Azacitidine and venetoclax in previously untreated acute myeloid leukemia;DiNardo;N. Engl. J. Med.,2020
5. U.S. Food, Drug Administration, 2018.Highlights of Prescribing Information: Venclexta; 2018." 2018.
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献